FAP Imaging and Theranostics: How to Cross the Finish Line

Phillip Kuo, MD, PhD, FACR

Consultant, Perceptive Imaging

Dr. Kuo is an internationally recognized physician-scientist. He played a pivotal role in the landmark VISION trial with Endocyte and Novartis, leading imaging eligibility design and quantitative PSMA PET analytics using AI. His academic career spans molecular imaging, MR, and radiopharmaceutical development, with notable contributions in dopaminergic imaging and neuro-oncologic theranostics. Dr. Kuo is deeply engaged in Alzheimer’s research, shaping appropriate use criteria and procedural guide

Dan Pryma, MD

VP, Global Clinical Development, Eli Lilly and Company

Dan Pryma, MD is Vice President, Global Clinical Development at Eli Lilly & Co overseeing clinical development of the radioligand therapy portfolio. He is a nuclear medicine physician and was previously the Gerd Muehllehner Professor of Radiology and Chief of the Division of Nuclear Medicine Imaging and Therapy at the Perelman School of Medicine as well as the Associate Director for Clinical Research of the Abramson Cancer Center at the University of Pennsylvania.

Jeremie Calais, MD, PhD

Assoc. Prof., Dept. of Molecular & Medical Pharmacology; Director, Theranostics, UCLA

Dr. Calais is an Assoc. Editor of The Journal of Nuclear Medicine and a Faculty Board Member of multiple organizations and committees such as the Jonsson Comprehensive Cancer Center at UCLA, the Institute of Urologic Oncology at UCLA, the Physics and Biology in Medicine Graduate Program at UCLA, the Correlative Imaging Council (CIC) of the SNMMI, the Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Melbourne, the SWOG Cancer Research Network or the Oncidium Foundation, Belgium.

Sherly Mosessian, PhD

Chief Scientific Officer, SOFIE Biosciences

As CSO of SOFIE Biosciences, Dr. Mosessian formulates the strategic plan for quality, compliance, regulatory, and scientific objectives of the organization, including leading the radiopharmaceutical diagnostic clinical development program. She previously served as CAO at UCLA and oversaw the establishment of a robust pathway for translation of PET tracers from bench to clinic, along with a GMP facility in support of PET radiopharmaceuticals production for research and clinical service.

Gregory Frank, PhD

Global Scientific Partnering Strategy Lead, Oncology, GE Healthcare

Dr. Frank has deep domain experience building partnerships in research, biotech, pharma, healthcare, and medicine across all phases of development. He currently leads partnering strategy for molecular imaging tracers in oncology including 68Ga-FAPI-46. The goal is to leverage these PET tracers while they are in clinical development and make them available to biotech and pharma partners who want to use them for imaging in their own clinical trials.

Joseph Vacca

Vice President & General Partner, Radiopharmaceuticals, Perceptive Imaging

Joe is a senior leader in the radiopharmaceutical and imaging industry with 18+ years of experience spanning commercial strategy, scientific collaboration, and operational execution. He has led/overseen contracting, acct. management, and executive delivery for 200+ preclinical & clinical radiopharmaceutical studies, including programs that contributed to the approval of diagnostic and therapeutic agents, enabling sponsors to advance complex programs from early development through approval.